|
WO2021041994A2
|
|
Machine learning methods for classifying cells
|
|
WO2021035194A1
|
|
Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
|
|
WO2020252218A1
|
|
Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
|
|
WO2020247832A1
|
|
Automated t cell culture
|
|
WO2020223571A1
|
|
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
|
WO2020223535A1
|
|
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
|
|
WO2020160050A1
|
|
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
|
WO2020113188A2
|
|
Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
|
|
WO2020113194A2
|
|
Methods for treatment using adoptive cell therapy
|
|
WO2020102770A1
|
|
Methods of dosing engineered t cells for the treatment of b cell malignancies
|
|
WO2020097403A1
|
|
Methods and combinations for treatment and t cell modulation
|
|
WO2020097132A1
|
|
Process for producing genetically engineered t cells
|
|
WO2020092848A2
|
|
Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
|
|
WO2020092854A2
|
|
Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
|
|
WO2020056047A1
|
|
Methods for mass spectrometry analysis of engineered cell compositions
|
|
AU2019316647A1
|
|
Methods for assessing integrated nucleic acids
|
|
SG11202101204TA
|
|
Processes for generating engineered cells and compositions thereof
|
|
WO2019213184A1
|
|
Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
|
|
AU2019247199A1
|
|
T cells expressing a recombinant receptor, related polynucleotides and methods
|
|
AU2019247200A1
|
|
Methods of producing cells expressing a recombinant receptor and related compositions
|
